Watch for Alector's October 13 R&D webinar detailing AL137, AL164, and AL062 pipeline data, which will inform the value of the wholly owned programs now funded by the Genentech deal. Also monitor Genentech's clinical development timeline for AL050 as it moves toward the clinic.
Price Chart
Executive Summary
Alector granted Genentech exclusive global rights to develop and commercialize AL050, a brain-penetrant GCase ERT for Parkinson's disease, receiving a $100M upfront payment with up to $1.17B in milestones plus tiered royalties. The deal validates Alector's ABC platform and extends cash runway into 2029, funding its wholly owned pipeline of Alzheimer's and Parkinson's programs.
Key Financial Metrics
Key Facts
- Alector receives $100M upfront from Genentech for exclusive global license to AL050 (GCase ERT for Parkinson's disease)
- Potential milestone payments up to $1.17B plus tiered royalties on net sales
- AL050 combines engineered GCase enzyme with Alector's proprietary ABC blood-brain barrier delivery platform
- Genentech responsible for all development, regulatory, manufacturing, and commercialization
- Alector retains ABC platform rights for wholly owned pipeline
- Cash runway extended into 2029; funds anti-Aβ antibody (AL137), tau siRNA (AL164), and alpha-synuclein siRNA (AL062) programs
- R&D webinar on wholly owned pipeline scheduled for October 13, 2026
Financial Impact
$100M upfront + up to $1.17B milestones + tiered royalties; cash runway extended into 2029
Risk Factors
- AL050 is preclinical; clinical development risks and potential regulatory setbacks remain
- Milestone payments are contingent on development, regulatory, and commercial achievements
- Competition from other GCase-targeting therapies and Parkinson's disease treatments
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3374409 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | SC 13G | $1.82 | awaiting T+60 | — | $1.83 (+0.55%) |
Oct 23, 2026 3d ago | SC 13G | $1.84 | awaiting T+60 | — | $1.83 (−0.33%) |
Oct 16, 2026 10d ago | 424B5 | $1.95 | awaiting T+60 | — | $1.83 (+6.15%) |
Oct 16, 2026 10d ago | 8-K | $1.95 | awaiting T+60 | — | $1.83 (+6.15%) |
Oct 14, 2026 12d ago | 8-K | $1.88 | awaiting T+60 | — | $1.83 (−2.66%) |
Oct 5, 2026 21d ago | 8-K | $1.99 | awaiting T+60 | — | $1.83 (−8.04%) |
Oct 5, 2026 21d ago | Press Release | $1.99 | awaiting T+60 | — | $1.83 (−8.04%) |
Sep 18, 2026 5w ago | SC 13G | $1.93 | awaiting T+60 | — | $1.83 (−5.18%) |
Sep 4, 2026 7w ago | Insider Cluster | $2.47 | awaiting T+60 | — | $1.83 (−25.91%) |
Aug 15, 2026 10w ago | Institutional Cluster | $2.05 | awaiting T+60 | — | $1.83 (−10.73%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers